+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Leishmaniasis (Kala-Azar) R&D Pipeline Drugs, Companies, Trials and Developments

  • ID: 4757702
  • Report
  • 100 pages
  • VPA Research
1 of 3
The global demand for Leishmaniasis (Kala-Azar) treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Leishmaniasis (Kala-Azar) are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Leishmaniasis (Kala-Azar) pipeline companies from advancing their products.

Leishmaniasis (Kala-Azar) Report Description:

The H1- 2019 pipeline review report on Leishmaniasis (Kala-Azar) is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.

The Leishmaniasis (Kala-Azar) pipeline guide presents information on all active drugs currently being developed for Leishmaniasis (Kala-Azar). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Leishmaniasis (Kala-Azar) pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Leishmaniasis (Kala-Azar) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Leishmaniasis (Kala-Azar) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Leishmaniasis (Kala-Azar) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Leishmaniasis (Kala-Azar) pipeline report includes:
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
For each pipeline product, the following details are provided:
  • Snapshot (Drug, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials
Reasons to Buy:
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Leishmaniasis (Kala-Azar) pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Leishmaniasis (Kala-Azar) pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Leishmaniasis (Kala-Azar) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days."
Note: Product cover images may vary from those shown
2 of 3
List of Tables
List of Figures

Global Leishmaniasis (Kala-Azar) Pipeline Overview
  • Key Findings, 2019
  • Disease Overview
  • Report Guide and Research Methodology
Executive Summary
  • Leishmaniasis (Kala-Azar) Drugs under active development, H1- 2019
  • Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
  • Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
  • Companies involved in Leishmaniasis (Kala-Azar) pipeline, H1- 2019
  • Mechanism of Action wise Leishmaniasis (Kala-Azar) Pipeline Candidates
Acea Biotech Inc Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Anacor Pharmaceuticals Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
BioLingus AG Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Cerenis Therapeutics Holding SA Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Daiichi Sankyo Co Ltd Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
DetectoGen Inc Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
DNDi Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Eurofins Advinus Ltd Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Farmabrasilis Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Fondation MEDINA Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
GlaxoSmithKline Plc Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
iCo Therapeutics Inc. Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Immune Modulation Inc Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
ManRos Therapeutics Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Matinas BioPharma Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Mologen AG Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Novartis AG Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Oblita Therapeutics BVBA Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Pfizer Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Rakta Therapeutics Inc Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Savant HWP Inc Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Sequella Inc Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
The Kindred Association Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Eisai Co Ltd Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Shionogi & Co Ltd Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Takeda Pharmaceutical Company Ltd Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
AstraZeneca Leishmaniasis (Kala-Azar) Pipeline Details
  • Business Profile
  • Drug Details
  • Drug Snapshot
  • Originator
  • Collaborator/Co-Developer
  • Route of Administration
  • Orphan Drug/Fast Track/Special Designation
  • Area
  • Type of Molecular Entity
  • Current Status
  • Drug Overview
  • Drug Mechanism of Action
  • Clinical/Pre-clinical Trial Details
  • Latest Drug Developments
Latest Leishmaniasis (Kala-Azar) Drug Pipeline Developments, 2019

Appendix
  • About the Publisher
  • Sources and Methodology
  • Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4757702
Adroll
adroll